US firm ties up with Pakistan’s Pharmaceutical Company for COVID-19 Drug Supply
US-based firm Gilead Sciences Inc said it had signed non-exclusive licensing pacts with five generic pharmaceutical manufacturers based in Pakistan and India to expand the supply of its experimental COVID-19 treatment “Remdesivir.”
The treaties enable the companies – Jubilant Life Sciences Ltd, Cipla Ltd, Hetero Labs Ltd, Mylan NV, and Ferozsons Laboratories Ltd – to produce and market the drug in 127 countries.
The countries consist of nearly all low-income and lower-middle-income ones, as well as several that are upper-middle- and high-income countries that face significant obstacles to healthcare access.
The licensees will likewise set their prices for the product they manufacture, Gilead announced.
The licenses are royalty-free until the World Health Organization announces the termination of the public health crisis about COVID-19, or until a product other than Remdesivir or a vaccine is authorized to use or prevent COVID-19, the organization announced.
Separately, in a declaration to the Pakistan Stocks Exchange, Ferozsons Laboratories notified that its listed subsidiary BF Biosciences Limited (BFBL) had approved an alliance with Gilead Sciences Inc for making and selling Remdesivir.
“Once production begins, we are sure that BFBL will have enough amounts overtime to help the requirements of the patients in Pakistan and access countries overseas,” the notice stated.
Gilead’s antiviral medication Remdesivir earlier this month acquired the U.S. Food and Drug Administration’s emergency use permission to treat COVID-19 cases.
The approval was the most advanced step in a global drive to discover viable treatments and a vaccine for the coronavirus. Remdesivir, which is applied through an injection, was already available to some sufferers who enlisted in clinical trials, or who tried it out on a “compassionate use” basis.
The Food and Drug Administration, which allowed the approval, explains severe as having low blood oxygen levels, needing oxygen therapy, or living on a ventilator.
In a trial comprising more than 1,000 people, the US National Institute of Allergy and Infectious Diseases (NIAID) noticed that hospitalized COVID-19 patients with respiratory trouble got better faster than those on a placebo. Precisely, patients on the medication had a 31% quicker time to recovery.
With no other authorized treatment for COVID-19, the respiratory sickness induced by the novel coronavirus, interest in Remdesivir has been increasing, and the firm is being strictly observed on the pricing and distribution of the short supply of the drug.
Gilead last week stated it was negotiating long-term licenses with various pharmaceutical manufacturers in India and Pakistan to produce Remdesivir for developing nations and that it would give technology to support the production.
The pandemic has killed nearly 295,000 people globally, according to an AFP tally, and various drugmakers are rushing to produce a viable treatment or vaccine to fight the outbreak.